Hezkue sildenafil oral suspension with alcohol in erectile dysfunction

Phase 2, randomised, open-label trial of ASP-001 in erectile dysfunction (ED) (2 arms), sponsored by Aspargo Laboratories. Primary endpoints: Time to Onset of Effect as Assessed by Participant-Reported Erectile Response at 4 hours and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration of Sildenafil at 24 hours. Planned start Apr 2026; status: not yet recruiting.